Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 10/2016

01-10-2016 | Erratum

Erratum to: TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer

Authors: Hui Jiang, Xueying Mao, Xiaoyi Huang, Jing Zhao, Lumei Wang, Jingjing Xu, Hongwei Zhang, Yongjie Lu, Yongwei Yu

Published in: Tumor Biology | Issue 10/2016

Login to get access

Excerpt

Erratum to: Tumor Biol. …
Metadata
Title
Erratum to: TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer
Authors
Hui Jiang
Xueying Mao
Xiaoyi Huang
Jing Zhao
Lumei Wang
Jingjing Xu
Hongwei Zhang
Yongjie Lu
Yongwei Yu
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5132-9

Other articles of this Issue 10/2016

Tumor Biology 10/2016 Go to the issue

Original Article

The suppressor of cytokine signaling 2 (SOCS2) inhibits tumor metastasis in hepatocellular carcinoma

Original Article

Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L

Original Article

ASPP2 suppresses stem cell-like characteristics and chemoresistance by inhibiting the Src/FAK/Snail axis in hepatocellular carcinoma

Original Article

Myopodin methylation is a prognostic biomarker and predicts antiangiogenic response in advanced kidney cancer

Original Article

MBD3 mediates epigenetic regulation on EPAS1 promoter in cancer

Original Article

miR-137 plays tumor suppressor roles in gastric cancer cell lines by targeting KLF12 and MYO1C
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits